Pharm D Solutions Recalls Epi-Shugarcaine Kit Due to Sterility Concerns
Pharm D Solutions is recalling 70 bottles of Epi-Shugarcaine Kit Solution because the company cannot ensure the product is sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for potential serious, reversible health consequences.
Plain-English summary
Pharm D Solutions, LLC is recalling 70 bottles of Epi-Shugarcaine Kit Solution (NDC 69699-1409-60). The recall was initiated because the company lacks assurance of the product's sterility.
The affected product was distributed nationwide. The specific lot code is 08272018:79, with a discard-by date of October 1, 2018.
Consumers and healthcare providers should stop using the recalled product and contact Pharm D Solutions for further instructions or a refund.
The recalled product
- Product
- Epi-Shugarcaine Kit Solution Pharm D Solutions, Houston, Texas --- NDC 69699-1409-60
- Manufacturer
- Pharm D Solutions, LLC
- Category
- Drug — Injectable Solution
- Affected units
- 70
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 08272018:79 Discard by: 10/1/2018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Pharm D Solutions, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Pharm D Solutions, LLC
See all →- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 &6 Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls B-Complex Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereFDA Recalls Ipamorelin Acetate Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Testosterone Cypionate Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
Same hazard · sterility
See all →- SevereFDA Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-28
- SevereHeparin Sodium Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-10-28
- SevereHouston Rx LLC Recalls Tirzepatide/Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-21
- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SeverePharm D Solutions Recalls Sermorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Human Chorionic Gonadotropin Vials Due to Sterility Concerns
FDA (Drugs) · 2018-12-26
- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Human Chorionic Gonadotropin Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Nandrolone Decanoate Injectable Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Testosterone Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19